Αρχική World News FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma World News FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma Από Ogkologos - 13 Νοεμβρίου, 2025 534 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR A Painful Breast Lump May Be Mistaken For Cancer When It’s... 15 Ιουλίου, 2020 ¿Qué deben saber las personas con cáncer sobre el consumo de... 11 Ιανουαρίου, 2022 Today is Giving Tuesday 1 Δεκεμβρίου, 2020 How Writing Helped Me Cope During Cancer 27 Απριλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... Girl’s New College Dorm Has Perfect View Of The Hospital Room... What’s Your Mantra? To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution